haematology

News in brief: PVd triplet therapy now on PBS for MM patients after first relapse; Peter Mac turns to Asia for immunotherapy vectors; Cryopreserved HPC products may be damaged goods in pandemic

PVd triplet therapy now on PBS for MM patients after first relapse Pomalidomide (Pomalyst) in combination with bortezomib and dexamethasone (PVd) will be reimbursed on the PBS from 1 October for patients with relapsed or refractory  multiple myeloma who have received at least one prior treatment regimen including lenalidomide. According to distributor Bristol Myers Squibb, ...

Already a member?

Login to keep reading.


OR
© 2021 the limbic